Median Technologies is pioneering next-generation software as a medical device and imaging services, leveraging advanced AI to improve the precision of cancer early diagnosis and treatment. Our offerings feature iCRO, providing central imaging services and AI based image analysis for oncology trials, and eyonis®, an AI/ML-powered suite of Software as a Medical Device (SaMD). We empower biopharma companies and clinicians to accelerate the development of innovative therapies and elevate patient care. Headquartered in France with operations in the U.S. and China, Median Technologies is listed on Euronext Growth. | A pioneer in applying artificial intelligence technologies to medical imaging, Median Technologies develops and markets eyonis® — a suite of AI-powered Software as a Medical Device for the early diagnosis of solid tumor cancers. The first device of the eyonis® portfolio, eyonis® LCS, is designed for lung cancer screening procedures. eyonis® LCS is currently under review for FDA 510(k) clearance in the U.S. and CE marking in Europe. In addition to its Software as a Medical Device business, Median also provides central imaging services and AI-based image analysis for oncology clinical trials in the biopharmaceutical industry through its iCRO business.
maihub
maihub is a medical AI platform development company based in South Korea, specializing in integrating various diagnostic AI solutions into a single system for hospitals. We provide integrated services to ensure AI is effectively used in real clinical settings. Our platform supports over 500 medical institutions in Korea and is expanding globally.
Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit’s FDA-cleared Lunit INSIGHT suite supports cancer screening at over 6,500 medical institutions in more than 65 countries. The company acquired Volpara Health, bringing together world-leading science and intelligent AI for early detection, mammography quality compliance, and cancer risk into a single, comprehensive ecosystem. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
Keya Medical
Keya Medical is a global medical technology company specializing in deep learning–driven solutions for disease diagnosis and treatment. Its flagship product, DEEPVESSEL FFR, is an AI-powered, non-invasive CT-based fractional flow reserve (FFR) analysis. FDA-cleared, CE-marked, and NMPA-approved, DEEPVESSEL FFR utilizes advanced deep learning algorithms to provide physiological functional assessments of the coronary arteries from standard coronary CT angiography (CCTA), enabling clinicians to diagnose and manage coronary artery disease accurately.
JS TECHWIN Co., Ltd.
JS TECHWIN is a South Korean leader in real-time radiation measurement for medical, industrial, and security applications. We design and manufacture real-time personal dosimeters, portable detectors, and high-precision gamma probes trusted by professionals worldwide. Experience next-level accuracy, reliability, and performance at CES 2026 | JS TECHWIN is a leading South Korean company specializing in radiation measurement and detection technologies for the medical, industrial, and security sectors. We develop and manufacture real-time portable detectors, high-precision gamma probes, and personal dosimeters widely used in hospitals, nuclear facilities, and industrial sites worldwide. Renowned for accuracy, reliability, and innovation, our products deliver customized radiation safety solutions trusted by professionals around the globe. Through continuous research, development, and technical support, JS TECHWIN is advancing global radiation safety and protecting human health. Visit our booth to experience our innovative technologies and feel the performance difference.
Intelerad
At Intelerad, we believe the path to answers in healthcare should be clear — whether you’re waiting for a diagnosis, or trying to expedite one. Our medical imaging solutions streamline the flow of information, simplifying complex processes, maximizing efficiencies, and shining a light on the unknown. We empower physicians to get patients the answers they need faster, and improve outcomes for everyone. With more accessible imaging, we’re getting patients out of the dark.
Hyland Healthcare
Hyland Healthcare provides innovative, connected healthcare solutions designed to unlock the power of unstructured content and medical imaging across your enterprise. By seamlessly integrating this data with core systems like electronic health records (EHR) , Hyland delivers a comprehensive suite of content services and enterprise imaging tools tailored for modern healthcare organizations. Our solutions bring together documents, medical images, and clinically rich data to the people who need it most—accelerating business processes, streamlining clinical workflows, and enabling smarter, more informed decision-making. Key Features: • Enterprise Imaging Solutions: Support patient care with secure, consolidated medical imaging workflows that streamline operations and enhance clinical decisions. • Content & Image Integration: Embed documents and imaging data directly into your EHR workflows for a single source of truth. • Advanced Interoperability: Break down silos to create a continuous, holistic view of patient information across the healthcare enterprise. • Cloud Modernization: Enhance scalability and configurability with solutions that grow alongside your organization. Trusted by more than 50% of U.S. health systems and 85% of HIMSS EMRAM Stage 7 achievers, Hyland Healthcare empowers healthcare providers to deliver their best. Our customizable solutions simplify complexity, enabling your teams to focus on what truly matters—better patient outcomes and operational excellence. Discover how Hyland can transform your healthcare enterprise. Connect with an expert today.
Heuron
Heuron delivers AI-powered imaging solutions that enhance clinical decision-making in the diagnosis of brain diseases. Heuron AgingCare Suite™ enables early identification of Alzheimer’s and Parkinson’s disease through MRI analysis, supporting timely diagnosis and improved diagnostic confidence. In acute stroke care, Heuron StroCare Suite™ provides rapid detection of critical conditions such as hemorrhage and ischemia, reducing treatment delays and contributing to better patient outcomes. Designed for seamless integration into existing clinical workflows, Heuron’s solutions offer a practical, effective way to improve both diagnostic speed and accuracy in everyday medical practice.
HeartLung.AI
HeartLung.AI is a health-tech company aiming to bring AI-enabled early detection and prevention of cardiovascular disease and lung cancer to mass adoption. Additionally, the AI help physicians to opportunistically detect osteoporosis, fatty liver disease, and other cardiometabolic abnormalities such as myosteatosis. HeartLung Technologies Received FDA “Breakthrough” Designation and Marketing Authorization for AutoChamber™: The first AI that enables opportunistic detection of hidden heart disease in millions of chest CT scans. HeartLung cleared FDA 510(k) for AutoBMD which is the only DEXA-equivalent, CT-based opportunistic osteoporosis screening applicable to 25+ million CT scans of the chest and abdomen every year. HeartLung is awaiting approval for AI-CVD™ which includes multiple AI modules including AutoCAC™ (Automated Coronary Artery Calcium Scoring based on the legacy Agatston score) and AI-CAC ™ the new calcium scoring technique powered by AI, also referred to as “Agatston 2.0”. HeartLung is initially focused on opportunistic screening in chest CT scans as the lowest hanging fruit for preventive care. To use HeartLung.AI services no hardware or software installation is required—simply sign up within 5 minutes at www.provider.heartlung.ai and connect your PACS to HeartLung.AI cloud and receive AI-generated DICOMized PDF reports sent directly back to your PACS. This seamless integration allows for immediate use without changing existing workflow. Additionally, referring physicians manually upload CT scans and receive instant AI-generated reports. Similar AI-CVD will empower hospitals and diagnostic imaging centers to provide their patients with fast, actionable data for multiple diseases all from a single chest CT scan. HeartLung Technologies is positioned to lead the future of AI-enabled preventive imaging to fight the number 1 and 2 causes of death namely cardiovascular disease, and lung cancer. HeartLung’s innovations, including AI-CVD™, AI-CAC™, AutoChamber™, and AutoBMD™, are designed to empower hospitals and imaging centers with precision prevention technology at population scale.